CXCL8 and pachyonychia congenita: As further investigations shed light on the predictive and therapeutic outcome value of IL-8 levels as a biomarker, the stand-alone utility and in combination with other biomarkers, like NLR, will hopefully become standard in treatment algorithms to gauge prognosis and steer treatment options, especially for patients suffering from PC.